课题基金 / 基金详情

Cholangiocyte-Derived Endothelin Signaling Mediates Biliary Injury and Liver Fibrosis

Cholangiocyte-Derived Endothelin Signaling Mediates Biliary Injury and Liver Fibrosis
胆管细胞衍生的内皮素信号传导介导胆道损伤和肝纤维化
批准号:
10552550
负责人:
Lindsey Kennedy
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-01-01 至 2024-12-31

项目摘要

项目成果

Lindsey Kennedy的其他基金

相似基金

相关文献

中文摘要
翻译
本申请的主要目的是阐明介导胆汁衰老的信号机制 和原发性硬化性胆管炎(PSC)期间的血管生成。已知(i)内皮素(ET)-1 信号传导在阻塞性胆汁淤积的胆管结扎(BDL)模型中增强,(ii)它主要被上调 和(iii)通过肝星状细胞(HSC)活化增强肝纤维化。在肝脏之外, ET-1是一种强有力的血管收缩剂,可增强转化生长因子-β1(TGF-β1,促血管生成因子) 在血管内皮细胞(VECs)中表达。总的来说,目前还不清楚ET信号(包括ET-2和ET-1)是如何传递的。 3)介导PSC期间的胆管衰老和VEC增殖/血管生成。此外, PSC期间的血管床和VEC增殖是未知的。ET-1、ET-2、ET-3、ET-A、ET-1、ET-2、ET-3、ET-1、ET-3、ET-1、ET-2、ET-3、ET-1、ET-3、ET-4、ET- ET-B增加,特别是在胆管细胞和血管内皮细胞中,在人PSC和多药耐药-2 PSC敲除(Mdr 2-/-)小鼠模型。此外,我们有新的初步数据显示, 在人PSC和Mdr 2-/-小鼠中的增殖和血管生成。血管生成与 胆汁淤积时的血管减少是有争议的,但考虑到PSC伴门静脉高压症患者有一个 发病率和死亡率增加,可能会发生一些潜在的VEC介导的变化。因此,我们认为, 我们的新发现首次表明PSC期间肝VEC增殖和血管生成。此外,本发明还 这些发现是第一次深入研究PSC期间胆管细胞和VEC中的ET信号传导。我们提供数据 表明一个反馈环,ET信号促进TGF-β1表达,反过来又增加miR-11表达。 125 b/HIF-1α表达,已知其增加ET表达。这是第一个数据显示, ET/TGF-β1/miR-125 b/HIF-1α之间的正反馈环可使胆汁衰老和肝脏衰老持续 自分泌和旁分泌方式的纤维化。此外,我们还发现,抑制ET-A或ET-B在Mdr 2-/- 使用目前FDA批准的药物(用于治疗肺动脉高压)的小鼠减少了胆汁分泌, 衰老和肝纤维化。我们的总体假设是胆管细胞和 肝VEC通过内皮素ET/TGF-β1信号传导相互交流, 衰老和VEC血管生成通过自分泌和旁分泌机制。我们的发现可能会导致 涉及鉴定用于治疗PSC的新的、有效的治疗剂。这一应用提案是第一个 独立性发展的第一步,林赛·肯尼迪博士。这一建议优雅地结合了 她的导师在胆管细胞生物学,microRNA信号和血管生成方面的背景工作, 技术和概念,进一步深入研究胆汁淤积期间的血管生物学。成功后 完成本申请后,Kennedy博士将更好地了解血管生成/血管减少,VEC 生物学和血管与胆管的相互作用,这可以发展成独立的研究。关键 这项研究提案的要素是(i)强大的指导团队,他们将提供顶级的 对申请人进行培训,(ii)引进新技术(墨水注入,腐蚀铸造,VEC隔离, 人原代细胞分离)和概念(胆汁淤积中的血管生物学),(iii)全面指导和 职业规划,包括一对一培训、会议出席、演讲机会和发展 (iv)申请人有机会发展自己独立、成功的研究 实验室
英文摘要
The main goal of this application is to clarify the signaling mechanisms mediating biliary senescence and angiogenesis during primary sclerosing cholangitis (PSC). It is known that (i) endothelin (ET)-1 signaling is enhanced in the bile duct ligation (BDL) model of obstructive cholestasis, (ii) it is primarily upregulated in cholangiocytes and (iii) enhances liver fibrosis via hepatic stellate cell (HSC) activation. Outside of the liver, ET-1 is a potent vasoconstrictor and enhances transforming growth factor-β1 (TGF-β1, pro-angiogenic factor) expression in vascular endothelial cells (VECs). Overall, it is unknown how ET signaling (including ET-2 and ET- 3) mediate biliary senescence and VEC proliferation/angiogenesis during PSC. Additionally, changes in the vascular bed and VEC proliferation during PSC is unknown. We found that ET-1, ET-2, ET-3 and ET-A and ET-B are increased, particularly in cholangiocytes and VECs, in human PSC and the multidrug resistance-2 knockout (Mdr2-/-) mouse model of PSC. Furthermore, we have novel preliminary data showing increased VEC proliferation and angiogenesis in both human PSC and in Mdr2-/- mice. Changes in angiogenesis versus vasopenia during cholestasis is controversial, but considering PSC patients with portal hypertension have an increased morbidity and mortality, there is likely some underlying VEC-mediated changes occurring. Therefore, our novel findings are the first to indicate liver VEC proliferation and angiogenesis during PSC. Additionally, these findings are the first to delve into ET signaling in cholangiocytes and VECs during PSC. We provide data indicating a feedback loop, whereby ET signaling promotes TGF-β1 expression, which can in turn increase miR- 125b/HIF-1α expression, which is known to increase ET expression. These are the first data demonstrating a positive feedback loop between ET/TGF-β1/miR-125b/HIF-1α that can perpetuate biliary senescence and liver fibrosis in autocrine and paracrine manners. Furthermore, we found that inhibition of ET-A or ET-B in Mdr2-/- mice using currently FDA-approved drugs (for the treatment of pulmonary hypertension) reduces biliary senescence and liver fibrosis when compared to controls. Our overall hypothesis is that cholangiocytes and liver VEC communicate with one another via endothelin ET/TGF-β1 signaling that increases biliary senescence and VEC angiogenesis through autocrine and paracrine mechanisms. Our findings may lead to the identification of new, effective therapeutics for the treatment of PSC. This application proposal is the first step to developing independence for the PI, Dr. Lindsey Kennedy. This proposal elegantly marries the background work of her mentors on cholangiocyte biology, microRNA signaling and angiogenesis with new techniques and concepts that further delve into vascular biology during cholestasis. Following successful completion of this application, Dr. Kennedy will have a better understanding of angiogenesis/vasopenia, VEC biology and vascular interactions with the bile ducts, and this can develop into independent studies. The KEY ELEMENTS of this research proposal are the (i) strong mentoring team developed, who will provide top-tier training for the applicant, (ii) introduction of new techniques (ink injection, corrosion casting, VEC isolation, human primary cell isolation) and concepts (vascular biology in cholestasis), (iii) comprehensive mentoring and career plan, including one-on-one training, conference attendance, presentation opportunities and development of grantsmanship, and (iv) opportunity for the applicant to develop her own independent, successful research lab.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Cholangiocyte-Derived Endothelin Signaling Mediates Biliary Injury and Liver Fibrosis
  • 批准号:
    10341130
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2021
  • 负责人:
    Lindsey Kennedy
  • 依托单位:
国内基金
海外基金
膀胱癌细胞通过调控淋巴内皮细胞angiopoietin-2修饰促进淋巴转移的分子机制研究
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    54.7万元
  • 批准年份:
    2021
  • 负责人:
    何旺
  • 依托单位:
中药单体蟾毒灵调控Angiopoietin-2蛋白分泌抑制肝癌血管生成的分子机制研究
  • 批准号:
    81603348
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    17.0万元
  • 批准年份:
    2016
  • 负责人:
    王海永
  • 依托单位:
肿瘤包绕型血管关键分子Angiopoietin-2在肝癌的表达调控机制及其功能
  • 批准号:
    81602151
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    18.0万元
  • 批准年份:
    2016
  • 负责人:
    周慧超
  • 依托单位:
炎症与淋巴管再生: Angiopoietin-2的调控作用
  • 批准号:
    30772262
  • 项目类别:
    面上项目
  • 资助金额:
    30.0万元
  • 批准年份:
    2007
  • 负责人:
    刘宁飞
  • 依托单位: